DR. ERIC CHRISTOPHER OLSON, D.C.
Chiropractic at Central Pkwy, San Antonio, TX
License number
Texas 13119
Category
Chiropractic
Type
Chiropractor
Address
Address
2
911 Central Pkwy N STE 300, San Antonio, TX 78232
3219 Southwestern Blvd, Dallas, TX 75225
3219 Southwestern Blvd, Dallas, TX 75225
Phone
(210) 477-4965
(210) 468-0682 (Fax)
(214) 537-2261
(214) 691-3809 (Fax)
(210) 468-0682 (Fax)
(214) 537-2261
(214) 691-3809 (Fax)
Personal information
See more information about ERIC CHRISTOPHER OLSON at radaris.comName
Address
Phone
505 Durham Dr, Arlington, TX 76014
5625 Hathaway Ct, Midland, TX 79707
5911 Camino Seco, Austin, TX 78731
Professional information
See more information about ERIC CHRISTOPHER OLSON at trustoria.com
Methods And Compositions Relating To Mek5 And Cardiac Hypertrophy And Dilated Cardiomyopathy
Methods And Compositions Relating To Mek5 And Cardiac Hypertrophy And Dilated Cardiomyopathy
US Patent:
2005026, Nov 24, 2005
Filed:
Mar 24, 2005
Appl. No.:
11/089425
Inventors:
Eric Olson - Dallas TX, US
Rebekka Nicol - Hicksville NY, US
Rebekka Nicol - Hicksville NY, US
International Classification:
A61K038/17
US Classification:
514012000
Abstract:
The present invention relates to compositions and methods relating to MEKand its role in heart disease. This protein has now been identified as a target for therapeutic intervention due to its role molecular events that lead to or contribute to cardiac hypertrophy and/or dilated cardiomyopathy. In particular, inhibition of MEKactivity will lead to decrease signalling of the pathways and reduce or eliminate the effects on sarcomere assembly, which in turn result or contribute to cardiac dysfunction. Also provided are transgenic animals and methods of screening for inhibitors of MEK
Identification Of Micro-Rnas Involved In Neuromuscular Synapse Maintenance And Regeneration
Identification Of Micro-Rnas Involved In Neuromuscular Synapse Maintenance And Regeneration
US Patent:
8202848, Jun 19, 2012
Filed:
Mar 17, 2009
Appl. No.:
12/405859
Inventors:
Andrew Williams - Dallas TX, US
Eric Olson - Dallas TX, US
Eric Olson - Dallas TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 48/00
US Classification:
514 44, 536 245, 536 244, 536 2431
Abstract:
The present invention relates to the identification of miRNAs that are involved in the process of neuromuscular synaptic maintenance and regeneration following injury or disease. Modulation of these miRNAs is proposed as treatment for spinal cord injury and neurodegenerative disease.
Methods And Compositions Relating To Hdac 4 And 5 Regulation Of Cardiac Gene Expression
Methods And Compositions Relating To Hdac 4 And 5 Regulation Of Cardiac Gene Expression
US Patent:
6632628, Oct 14, 2003
Filed:
Aug 21, 2000
Appl. No.:
09/643206
Inventors:
Eric N. Olson - Dallas TX
Jianrong Lu - Quincy MA
Timothy McKinsey - Dallas TX
Jianrong Lu - Quincy MA
Timothy McKinsey - Dallas TX
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
C12Q 134
US Classification:
435 18, 435 29, 514 44
Abstract:
The present invention relates to cardiac hypertrophy. More particularly, the present invention defines the molecular events linking calcium stimulation to cardiac hypertrophy. More specifically, the present invention shows that Ca stimulation of the hypertrophic response is mediated through an HDAC 4 and 5 interaction with MEF2, and that phosphorylation of HDACs results in loss of HDAC-mediated repression of MEF2 hypertrophic action. Thus, the present invention provides methods and compositions of treating cardiac hypertrophy, as well as methods and compositions for identifying subjects at risk for cardiac hypertrophy. Further provided are methods for the detection of compounds having therapeutic activity toward cardiac hypertrophy.
Methods And Compositions Relating To Hdac 4 And 5 Regulation Of Cardiac Gene Expression
Methods And Compositions Relating To Hdac 4 And 5 Regulation Of Cardiac Gene Expression
US Patent:
2009008, Apr 2, 2009
Filed:
Sep 2, 2008
Appl. No.:
12/231311
Inventors:
Eric N. Olson - Dallas TX, US
Jianrong Lu - Quincy MA, US
Timothy McKinsey - Dallas TX, US
Jianrong Lu - Quincy MA, US
Timothy McKinsey - Dallas TX, US
International Classification:
A61K 48/00, A61K 38/46, C12Q 1/68, A61P 9/10
US Classification:
424 932, 424 946, 435 6
Abstract:
The present invention relates to cardiac hypertrophy. More particularly, the present invention defines the molecular events linking calcium stimulation to cardiac hypertrophy. More specifically, the present invention shows that Ca stimulation of the hypertrophic response is mediated through an HDAC 4 and 5 interaction with MEF2, and that phosphorylation of HDACs results in loss of HDAC-mediated repression of MEF2 hypertrophic action. Thus, the present invention provides methods and compositions of treating cardiac hypertrophy, as well as methods and compositions for identifying subjects at risk for cardiac hypertrophy. Further provided are methods for the detection of compounds having therapeutic activity toward cardiac hypertrophy.
Transgenic Animal Models For Cardiac Hypertrophy And Methods Of Use Thereof (Screening)
Transgenic Animal Models For Cardiac Hypertrophy And Methods Of Use Thereof (Screening)
US Patent:
2002005, May 9, 2002
Filed:
Jan 29, 2001
Appl. No.:
09/772503
Inventors:
Stephen Grant - Ft. Worth TX, US
Eric Olson - Dallas TX, US
Eric Olson - Dallas TX, US
Assignee:
Board of Regents The University of Texas System
International Classification:
C12Q001/00, A01K067/00
US Classification:
800/003000, 435/004000
Abstract:
Transgene constructs for generating transgenic animals, wherein the transgene encodes a gene product which modulates transcription of a hypertrophy-sensitive gene, are provided. Further provided are recombinant vectors comprising the transgenes of the invention. Further provided are transgenic animals generated using the transgene constructs. Further provided are enzyme-based, cell-based, and whole-animal-based assays for detecting substances having therapeutic activity toward cardiac hypertrophy. Further provided are compositions comprising substances which modulate levels of active product of a hypertrophy-sensitive gene. Further provided are methods of treating cardiac hypertrophy.
Micro-Rnas That Modulate Smooth Muscle Proliferation And Differentiation
Micro-Rnas That Modulate Smooth Muscle Proliferation And Differentiation
US Patent:
2011029, Dec 1, 2011
Filed:
Jul 14, 2011
Appl. No.:
13/183117
Inventors:
Eric OLSON - Dallas TX, US
Eric SMALL - Dallas TX, US
Mei XIN - Dallas TX, US
Eric SMALL - Dallas TX, US
Mei XIN - Dallas TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 9/00, A61K 31/7105, A61K 31/713, A61K 31/7088
US Classification:
424400, 514 44 R, 514 44 A
Abstract:
The present invention relates to the identification of microRNAs that regulate smooth muscle cell proliferation and differentiation, including the miR-143/miR-145 cluster. Methods of treating restenosis and neointima formation by increasing expression of miR-143 and/or miR-145 are disclosed. The present invention also relates to the identification of two microRNAs, miR-486 and miR-422a, that regulate cell survival in the heart. Methods of treating or preventing cardiac hypertrophy, heart failure, or myocardial infarction by increasing expression of miR-486 and/or miR-422a in heart tissue are also disclosed.
Modulation Of 5-Ht2 Receptors As A Treatment For Cardiovascular Diseases
Modulation Of 5-Ht2 Receptors As A Treatment For Cardiovascular Diseases
US Patent:
2005026, Dec 1, 2005
Filed:
Dec 21, 2004
Appl. No.:
11/018426
Inventors:
Erik Bush - Erie CO, US
Eric Olson - Dallas TX, US
Lawrence Melvin - Longmont CO, US
Eric Olson - Dallas TX, US
Lawrence Melvin - Longmont CO, US
International Classification:
A61K048/00, A61K039/395, A61K031/47, A61K031/4743
US Classification:
424143100, 514044000, 514002000, 514291000, 514313000
Abstract:
The present invention provides for methods of treating and preventing muscle atrophy, cardiac hypertrophy, heart failure and/or primary pulmonary hypertension linked to a family of serotonin receptors called 5-HT2 receptors. The present invention further demonstrates that modulators of 5-HT2 receptors can inhibit or treat muscle atrophy, heart failure, cardiac hypertrophy, and/or primary pulmonary hypertension.
Cardiac Repair By Reprogramming Of Cardiac Fibroblasts Into Cardiomyocytes
Cardiac Repair By Reprogramming Of Cardiac Fibroblasts Into Cardiomyocytes
US Patent:
2012021, Aug 23, 2012
Filed:
Feb 22, 2012
Appl. No.:
13/402609
Inventors:
Young-Jae Nam - Dallas TX, US
Kunhua Song - Dallas TX, US
Eric N. Olson - Dallas TX, US
Kunhua Song - Dallas TX, US
Eric N. Olson - Dallas TX, US
International Classification:
A61K 48/00, C12N 15/85, A61P 9/10, C12N 15/861, C12N 15/867, A61K 38/17, C12N 5/071, C12N 15/86
US Classification:
424 932, 435375, 435455, 435456, 514 44 R, 514 164
Abstract:
The present invention involves the use of transcription factors including Tbx5, Mef2C, Hand2, myocardin and Gata4 to reprogram cardiac fibroblasts into cardiomyocytes, both in vitro and in vivo. Such methods find particular use in the treatment of patients post-myocardial infarction to prevent or limit scarring and to promote myocardial repair.
Champ—A Novel Cardiac Helicase-Like Factor
Champ—A Novel Cardiac Helicase-Like Factor
US Patent:
7160720, Jan 9, 2007
Filed:
Feb 15, 2002
Appl. No.:
10/077583
Inventors:
Eric Olson - Dallas TX, US
Zhi-Ping Liu - Dallas TX, US
Zhi-Ping Liu - Dallas TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
C07H 21/04, C12N 15/63, C07K 14/00
US Classification:
4353201, 536 231
Abstract:
The present invention relates to a new polypeptide and the gene encoding therefore, said gene being regulated in cardiac tissue by the transcription factor MEF2C. This polypeptide, CHAMP (cardiac helicase activated by MEF2 protein), bears striking resemblance to a number of other helicase proteins and appears to play a role in RNA processing and transcriptional control in heart muscle. For example, CHAMP has been demonstrated to inhibit both hypertrophy of primary cardiomyocytes and proliferation of non-cardiac cells. Also disclosed are methods of using the gene and protein in drug screening and therapy, including, for example, use of the gene in gene therapy to treat cardiovascular disease.
Micro-Rnas That Modulate Smooth Muscle Proliferation And Differentiation And Uses Thereof
Micro-Rnas That Modulate Smooth Muscle Proliferation And Differentiation And Uses Thereof
US Patent:
7994150, Aug 9, 2011
Filed:
Feb 23, 2009
Appl. No.:
12/391028
Inventors:
Eric Olson - Dallas TX, US
Eric Small - Dallas TX, US
Mei Xin - Dallas TX, US
Eric Small - Dallas TX, US
Mei Xin - Dallas TX, US
Assignee:
Board of Regents, the University of Texas System - Austin TX
International Classification:
C12N 15/11, A61K 48/00
US Classification:
514 44A, 514 44 R
Abstract:
The present invention relates to the identification of microRNAs that regulate smooth muscle cell proliferation and differentiation, including the miR-143/miR-145 cluster. Methods of treating restenosis and neointima formation by increasing expression of miR-143 and/or miR-145 are disclosed. The present invention also relates to the identification of two microRNAs, miR-486 and miR-422a, that regulate cell survival in the heart. Methods of treating or preventing cardiac hypertrophy, heart failure, or myocardial infarction by increasing expression of miR-486 and/or miR-422a in heart tissue are also disclosed.